Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone Hemisuccinate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.81 |
| ▸ | PGR | P06401 | 4/20 | 0.81 |
| ▸ | AR | P10275 | 2/20 | 0.81 |
| ▸ | F2 | P00734 | 1/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL6 | P05231 | 1/20 | 0.52 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | GLUL | P15104 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone Hemisuccinate SCHEMBL2482645 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL29053159 | 0.99 | NR3C1 (0.98) | NR3C1CYP3A4PGRARF2 | |
| SCHEMBL10400906 | 0.95 | NR3C1 (0.91) | NR3C1CYP3A4PGRARF2 | |
| SCHEMBL14867434 | 0.95 | NR3C1 (0.90) | NR3C1CYP3A4PGRARF2 | |
| SCHEMBL14867431 | 0.95 | NR3C1 (0.90) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL1169509 | 0.92 | NR3C1 (0.85) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL10953512 | 0.92 | NR3C1 (0.85) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL40947 | 0.92 | NR3C1 (0.85) | NR3C1CYP3A4PGRARF2 | |
| SCHEMBL10910221 | 0.92 | NR3C1 (0.85) | NR3C1CYP3A4PGRARF2 | |
| SCHEMBL11044631 | 0.91 | NR3C1 (0.84) | NR3C1CYP3A4PGRARF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20250189542-A1 | DIAGNOSTIC OR PREDICTOR OF RELAPSING REMITTING MULTIPLE SCLEROSIS | DIGNITY HEALTH | 2025-06-12 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-12253531-B2 | Diagnostic or predictor of relapsing remitting multiple sclerosis | DIGNITY HEALTH (US) | 2025-03-18 | — | — | US | claimed |
| EP-4521117-A2 | DIAGNOSTIC OR PREDICTOR OF RELAPSING REMITTING MULTIPLE SCLEROSIS | Dignity Health (US) | 2025-03-12 | — | — | EP | claimed |
| US-20240408305-A1 | Medication Delivery Device | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-12-12 | — | — | US | claimed |
| US-20240228574-A9 | METHODS OF TREATING CANCER | ALX Oncology Inc. | 2024-07-11 | — | — | US | claimed |
| US-20240132567-A1 | METHODS OF TREATING CANCER | ALX ONCOLOGY INC (US) | 2024-04-25 | — | — | US | claimed |
| US-20240094225-A1 | DIAGNOSTIC OR PREDICTOR OF RELAPSING REMITTING MULTIPLE SCLEROSIS | DIGNITY HEALTH | 2024-03-21 | — | — | US | claimed |
| US-20110052703-A1 | BETA-CASEIN ASSEMBLIES FOR MUCOSAL DELIVERY OF THERAPEUTIC BIOACTIVE AGENTS | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2011-03-03 | — | — | US | claimed |
| EP-2252266-A1 | BETA-CASEIN ASSEMBLIES FOR MUCOSAL DELIVERY OF THERAPEUTIC BIOACTIVE AGENTS | Yissum Research Development Company of the Hebrew University of Jerusalem (IL) | 2010-11-24 | — | — | EP | claimed |
| WO-2009101613-A1 | BETA-CASEIN ASSEMBLIES FOR MUCOSAL DELIVERY OF THERAPEUTIC BIOACTIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-08-20 | — | — | WO | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| EP-1755616-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | Advanced Ocular Systems Limited (AU) | 2007-02-28 | — | — | EP | claimed |
| WO-2005099715-A9 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD | 2007-02-15 | — | — | WO | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| US-20050245497-A1 | Treatment of ophthalmic conditions | EYE CO PTY LTD (AU) | 2005-11-03 | — | — | US | claimed |
| WO-2005099715-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD. (AU) | 2005-10-27 | — | — | WO | claimed |
| WO-2003082251-A2 | THE EFFERVESCENT PHARMACEUTICAL DOSAGE FORM OF ESTERS AND ESTER SALTS OF 6 α METHYLPREDNISOLONE SUCCINATE, PROCEDURE FOR ITS OBTAINING AND APPLICATION | HEMOFARM KONCERN A.D. PHARMACEUTICAL AND CHEMICAL INDUSTRY (YU) | 2003-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | NR3C1 413/4885CYP3A4 1322/4885PGR 2470/4885 |
| US-20050245497-A1 | Treatment of ophthalmic conditions | MC2R, NR3C2, PTGIR | NR3C1 6/4885CYP3A4 4201/4885PGR 529/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | NR3C1 2270/4885CYP3A4 3750/4885PGR 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.